Menopause & Weight Gain: Estrogen’s Connection to GLP-1 Agonists
Menopause is a natural phase of life that often brings significant hormonal shifts. One of the most common challenges faced by women during this time is weight gain, which affects approximately 70% of menopausal women. Beyond aesthetics, this weight gain often correlates with changes in body composition, such as increased abdominal fat and reduced muscle mass, which carry broader health implications.
GLP-1 Drugs: Entering a New Era in the World of Weight Loss
The drug semaglutide belongs to a class of medications known as Glucagon-like-peptide-1 receptor agonists, or GLP-1 receptor agonists. It mimics the GLP-1 hormone, released in the gut in response to eating. Semaglutide was designed for type 2 diabetes and has shown great potential in helping patients with diabetes. These GLP-1 analogues revealed several effects, including slowing stomach emptying, acting on the brain to reduce appetite, and boosting insulin release, which helps regulate blood sugar levels. It may also result in reduced risk of cancer, diabetes, and heart disease in people who are obese or overweight.
A Deeper Look into Low Dose Naltrexone (LDN): Research & Insights
Naltrexone is an opiate receptor antagonist. The 50-mg dose of Naltrexone was approved by the FDA for opioid and alcohol addiction in 1984. At much lower doses (0.5–9 mg per day), it may provide relief to patients suffering from autoimmune diseases, chronic pain, mental health diseases, and inflammation.
Low Dose Naltrexone: A Medical Game Changer
ScriptWorks has spent hours and hours researching and collaborating with healthcare professionals on Low Dose Naltrexone since 2014. Doctors and pharmacists around the world continue to study this fascinating therapy.